Clinical Trial Update: Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the effects of mavoglurant (AFQ056) and baclofen on meal-induced gastroesophageal reflux in gastroesophageal reflux disease; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• AFQ056 (mavoglurant)
• BACLOFEN (Baclofen)

Snippet

Sponsor: Novartis | Conditions: Gastroesophageal Reflux Disease | Phase 1 | Status: COMPLETED